查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胃食管反流药物全球市场规模、份额、按类型分类的行业趋势分析报告（抗酸剂、质子泵抑製剂 (PPI)、H2 受体阻滞剂、促动力药），区域展望和预测，2022 年 2028-2028 年
市场调查报告书
商品编码
1261357

胃食管反流药物全球市场规模、份额、按类型分类的行业趋势分析报告（抗酸剂、质子泵抑製剂 (PPI)、H2 受体阻滞剂、促动力药），区域展望和预测，2022 年 2028-2028 年

Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 130 Pages | 订单完成后即时交付

价格

在预测期内，胃食管反流病市场规模预计将以 2.2% 的复合年增长率增长，到 2028 年达到 56 亿美元。

此外，患有胃酸反流的人可能会出现持续咳嗽、喉炎、喘息、灼痛或喉咙痛、哮喘加剧以及夜间睡眠困难。 在极少数情况下，持续反流会导致狭窄、食管炎、转化和恶性肿瘤。 下食管括约肌的内在压力、胸膈对 LES 的外在压迫以及希氏锐角被认为构成了抗反流屏障。 一过性 LES 鬆弛 (TLESR)、LES 低血压和食管胃交界处 (EGJ) 的物理障碍，即食管裂孔疝，已被确定为反流的三个最常见原因。

TLESR 发生在吞嚥过程中，并允许食团从食道进入胃部，是很大一部分健康人和 GERD 患者最重要的反流机制。 还诱导了二次蠕动，它通过迷走神经反射起源于食道中段，迷走神经反射启动主要位于下心区的胃感受器的激活。 因此，导致 TLESR 的主要因素是胃扩张，通常由胃中存在空气或食物引起。 这解释了为什么 TLESR 主要是餐后事件。

COVID-19 影响分析

COVID-19 大流行对市场产生了负面影响。 自大流行开始以来，COVID-19 对人类健康的影响一直备受争议，胃食管反流病 (GERD) 也不例外。 人们担心病毒可能会从 GI（胃肠道）道逸出，并通过肠肺轴在其他器官系统（例如呼吸系统）中引起症状、感染或炎症。 肠道是人体最大的免疫器官，可能含有快速生长的 COVID-19 病毒群落。 此类分析和研究表明 COVID-19 与 GERD 之间存在联繫，这极大地阻碍了市场的增长。

市场增长因素

过度进食快餐导致消化系统紊乱

快餐中含有各种毒素和化学物质以及过量的盐分，自然会增加腹胀、胃溃疡甚至胃癌的机率。 当您（从快餐中）吸收更多的盐分时，钠会导致更多的水分滞留，从而导致胃痛、腹部肿胀和腹胀。 成年人的快餐消费随着财富的增加而增加，随着年龄的增长而减少。 男性和女性的快餐消费量大致相同，男性在午餐时吃得更多，而女性在两餐之间吃得更多。 全球快餐消费的增长正在增加胃食管反流病的病例数量，推动市场的增长。

酒精消费激增

个人因素包括年龄、性别、家庭环境和社会经济地位。 虽然没有单一的风险因素占主导地位，但更容易出现酒精相关问题的人更有可能饮酒。 与富人相比，不太富裕的人因饮酒而面临更多的健康和社会问题。 研究还表明，饮酒会增加胃食管反流病的风险。 饮酒量的增加可能会影响这种疾病的总体患病率，并成为胃食管反流病市场扩张的推动力。

市场约束

与胃食管反流药物相关的副作用示例

抗酸剂会导致某些人过敏，并使他们更容易对某些食物过敏。 抗酸剂的副作用通常是由于剂量不当引起的。 一些抗酸剂含有钙，包括 Maalox、Mylanta、Rolaids 和 Tums。 如果患者服用的剂量超过或超过推荐量，则可能会出现钙过量。 钙摄入过多的症状包括噁心、呕吐、精神状态改变和肾结石。 钙摄入过多也会引起碱中毒。 在这种状态下，身体无法产生足够的酸来有效工作。 如果患者觉得他们需要服用大量抗酸剂才能感觉好些，则可能表明存在另一种疾病。

按类型划分的前景

根据类型，胃食管反流药物市场分为抗酸剂、H2 受体阻滞剂、质子泵抑製剂 (PPI) 和促动力剂。 2021 年，胃食管反流药物市场由质子泵抑製剂 (PPI) 部分主导。 这是因为它们是最常推荐用于治疗胃灼热和缺氧相关症状的一组药物。 这些药物通过抑制胃壁细胞产生酸来发挥作用。 PPI 可通过非处方药和处方药获得。 奥美拉唑和兰索拉唑是历史最悠久、医生和患者最为熟知的药物。

区域展望

按地区划分，对北美、欧洲、亚太地区和 LAMEA 的胃食管反流病市场进行了分析。 到 2021 年，北美将占据胃食管反流病市场的最高收入份额。 这是由于社区中 GERD 发病率的增加以及 GERD 药物使用的增加。 也有越来越多的运动来提高公众对该问题的认识，从而增加了对 GERD 治疗药物的需求。 该活动旨在为患有 GERD 的人提供一个简单的食谱来防止反流。

内容

第一章市场范围与研究方法

  • 市场定义
  • 目的
  • 市场范围
  • 细分
    • 全球胃食管反流药物市场：按类型分类
    • 全球胃食管反流药物市场：按地区
  • 调查方法

第 2 章市场概述

  • 介绍
    • 概览
      • 市场构成和情景
  • 影响市场的主要因素
    • 市场驱动力
    • 市场製约因素

第 3 章全球胃食管反流药物市场：按类型

  • 全球抗酸剂市场：按地区
  • 全球质子泵抑製剂 (PPI) 市场，按地区
  • 全球 H2 受体阻滞剂市场：按地区
  • 全球运动促进剂市场：按地区

第 4 章全球胃食管反流药物市场：按地区

  • 北美
    • 北美市场：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
      • 其他北美地区
  • 欧洲
    • 欧洲市场：按国家/地区分类
      • 德国
      • 英国
      • 法国
      • 俄罗斯
      • 西班牙
      • 意大利
      • 其他欧洲地区
  • 亚太地区
    • 亚太市场：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 韩国
      • 新加坡
      • 马来西亚
      • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 按国家/地区划分的拉丁美洲/中东/非洲市场
      • 巴西
      • 阿根廷
      • 阿拉伯联合酋长国
      • 沙特阿拉伯
      • 南非
      • 尼日利亚
      • 其他拉丁美洲/中东/非洲地区

第五章公司简介

  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • GlaxoSmithKline PLC（GSK）
  • Johnson & Johnson
  • Ironwood Pharmaceuticals, Inc
  • Eisai Co, Ltd.
  • Medigus Ltd
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc
  • Camber Pharmaceuticals, Inc（Hetero Labs Limited）

The Global Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 2.2% CAGR during the forecast period.

A digestive illness called gastroesophageal reflux disease (GERD) occurs when stomach contents, including acid, food, and liquids, leak into the esophagus. The lining of the esophagus is irritated, giving patients a burning feeling. Heartburn (reflux) and regurgitation are the primary esophageal symptoms defining GERD. Moreover, GERD may result in esophageal inflammation if ignored for a long time. It is linked to sleep problems and low quality of life.

Upper endoscopy, an ambulatory acid (PH) probe test, esophageal manometry, and X-rays are the primary methods used to diagnose it. Changing one's lifestyle and using regulated drugs might help manage certain conditions, but others may also need surgery or powerful medications. Burning in the chest, dysphagia, belching, epigastric discomfort, trouble swallowing, regurgitation of food or sour liquid, and a lump in the throat are typical indications and symptoms of the condition.

Moreover, acid reflux sufferers may have a persistent cough, laryngitis, wheezing, burning or painful throat sensations, increasing asthma, and sleep difficulties at night. In rare cases, persistent reflux may result in stricture, esophagitis, metaplasia, or malignancy. The lower esophageal sphincter's intrinsic pressure, the crural diaphragm's extrinsic compression of the LES, and the acute angle of His are hypothesized to make up the anti-reflux barrier. Transient LES relaxations (TLESRs), LES hypotension, and physical disruption of the esophagogastric junction (EGJ), or hiatus hernia, are the three most common causes of reflux.

TLESRs, which occur during swallows to allow the passage of a bolus from the esophagus into the stomach, are the most important mechanism of reflux in healthy subjects and a significant portion of GERD patients. They are also induced by secondary peristalsis, which starts from the mid-esophagus due to a vago-vagal reflex beginning with the activation of gastric receptors primarily located in the sub-cardiac region. As a result, the primary factor that causes a TLESR is stomach distension, often brought on by gastric air or the presence of food, which explains why TLESRs are mostly a postprandial event.

COVID-19 Impact Analysis

The COVID-19 pandemic affected the market negatively during the pandemic phase. COVID-19's effects on many aspects of human health have been extensively discussed since the start of the pandemic, and gastroesophageal reflux disease (GERD) is no exception. There was a worry that the virus may move beyond the GI (gastrointestinal) tract by generating symptoms in other organ systems, such as the respiratory system, through a gut-lung axis or by causing infection or inflammation. The gut, the body's biggest immunological organ, may be home to colonies of COVID-19 virus, which reproduces quickly. Because of the association between COVID-19 and GERD shown by such analysis and research, the market growth was hampered significantly.

Market Growth Factors

High intake of fast food causing digestive diseases

Fast food naturally raises the chance of bloating, stomach ulcers, and sometimes even stomach cancer since it includes a variety of hazardous substances, chemicals, and excessive amounts of salt. If the body absorbs more salt (from fast food), the sodium will retain more water, which may cause stomach pain and abdominal swelling or bloating. Fast food consumption among adults rose with wealth while decreasing with age. Fast food consumption was similar across men and women, with a more significant proportion of men eating it for lunch and a higher proportion of women eating it as a snack. The growing consumption of fast food globally will increase the cases of gastroesophageal reflux diseases and propel market growth.

The surging consumption of alcohol

Personal factors include age, gender, domestic circumstances, and socioeconomic status. Although no one risk factor predominates, those who are more vulnerable to alcohol-related problems are more likely to use alcohol. Less wealthy individuals have more significant health and social issues due to alcohol use than more affluent individuals. Studies have also shown that drinking alcohol increases the risk of gastroesophageal reflux disease. The growing use of alcohol will have an impact on the disease's overall prevalence and may help drive the gastroesophageal reflux diseases market expansion.

Market Restraining Factors

Some side effects associated with gastroesophageal reflux disease's medications

Antacids may cause allergies in certain persons and make it more likely for people to become allergic to certain foods. Antacid side effects are often caused by improper dosage. Several antacids include calcium, including Maalox, Mylanta, Rolaids, and Tums. A calcium overdose is possible if the patient takes them in excess or longer than recommended. Symptoms of too much calcium include nausea, vomiting, altered mental state, and kidney stones. Alkalosis may also result from too much calcium. The body can't produce enough acid in this state for it to work effectively. It might indicate another disease if the patient feels they need to take a lot of antacids to feel better.

Type Outlook

Based on type, the gastroesophageal reflux disease therapeutics market is segmented into antacids, H2 receptor blockers, proton pump inhibitors (PPIs) and pro-kinetic agents. The proton pump inhibitors (PPIs) segment acquired a significant revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is due to the fact that it is the most often recommended family of medications for treating heartburn and conditions linked to acidity. They work by inhibiting acid production in the stomach's parietal cells. Both over-the-counter and prescription PPIs are offered. Omeprazole and lansoprazole are two medications that have been around the longest and are thus the most well-known to doctors and patients.

Regional Outlook

Region-wise, the gastroesophageal reflux disease therapeutics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is owing to the increased incidence of GERD in the local population and the rising use of GERD therapies. Also, there are more and more campaigns to raise public awareness of the problem, driving up demand for GERD treatments. The campaign aimed to provide GERD sufferers with simple-to-follow recipes that are reflux-friendly.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

Market Segments covered in the Report:

By Type

  • Antacids
  • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Blockers
  • Pro-kinetic Agents

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigus Ltd.
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market, by Type
    • 1.4.2 Global Gastroesophageal Reflux Disease Therapeutics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition & scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market by Type

  • 3.1 Global Antacids Market by Region
  • 3.2 Global Proton Pump Inhibitors (PPIs) Market by Region
  • 3.3 Global H2 Receptor Blockers Market by Region
  • 3.4 Global Pro-kinetic Agents Market by Region

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market by Region

  • 4.1 North America Gastroesophageal Reflux Disease Therapeutics Market
    • 4.1.1 North America Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.1.1 North America Antacids Market by Country
      • 4.1.1.2 North America Proton Pump Inhibitors (PPIs) Market by Country
      • 4.1.1.3 North America H2 Receptor Blockers Market by Country
      • 4.1.1.4 North America Pro-kinetic Agents Market by Country
    • 4.1.2 North America Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.1.2.1 US Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.1.1 US Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.2 Canada Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.2.1 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.3 Mexico Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.4 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.4.1 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.2 Europe Gastroesophageal Reflux Disease Therapeutics Market
    • 4.2.1 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.1.1 Europe Antacids Market by Country
      • 4.2.1.2 Europe Proton Pump Inhibitors (PPIs) Market by Country
      • 4.2.1.3 Europe H2 Receptor Blockers Market by Country
      • 4.2.1.4 Europe Pro-kinetic Agents Market by Country
    • 4.2.2 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.2.2.1 Germany Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.1.1 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.2 UK Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.3 France Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.3.1 France Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.4 Russia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.4.1 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.5 Spain Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.5.1 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.6 Italy Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.7 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.7.1 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
    • 4.3.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.1.1 Asia Pacific Antacids Market by Country
      • 4.3.1.2 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country
      • 4.3.1.3 Asia Pacific H2 Receptor Blockers Market by Country
      • 4.3.1.4 Asia Pacific Pro-kinetic Agents Market by Country
    • 4.3.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.3.2.1 China Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.1.1 China Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.2 Japan Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.3 India Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.3.1 India Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.4 South Korea Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.4.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.5 Singapore Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.5.1 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.6 Malaysia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.6.1 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.7 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.7.1 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.4 LAMEA Gastroesophageal Reflux Disease Therapeutics Market
    • 4.4.1 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.1.1 LAMEA Antacids Market by Country
      • 4.4.1.2 LAMEA Proton Pump Inhibitors (PPIs) Market by Country
      • 4.4.1.3 LAMEA H2 Receptor Blockers Market by Country
      • 4.4.1.4 LAMEA Pro-kinetic Agents Market by Country
    • 4.4.2 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.4.2.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.1.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.2 Argentina Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.2.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.3 UAE Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.3.1 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.4 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.4.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.5 South Africa Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.5.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.6 Nigeria Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.6.1 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.7 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.7.1 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type

Chapter 5. Company Profiles

  • 5.1 Takeda Pharmaceutical Company Limited
    • 5.1.1 Company Overview
    • 5.1.2 Financial Analysis
    • 5.1.3 Regional Analysis
    • 5.1.4 Research & Development Expense
  • 5.2 AstraZeneca PLC
    • 5.2.1 Company Overview
    • 5.2.2 Financial Analysis
    • 5.2.3 Regional Analysis
    • 5.2.4 Research & Development Expenses
  • 5.3 GlaxoSmithKline PLC (GSK)
    • 5.3.1 Company Overview
    • 5.3.2 Financial Analysis
    • 5.3.3 Segmental and Regional Analysis
    • 5.3.4 Research & Development Expense
  • 5.4 Johnson & Johnson
    • 5.4.1 Company Overview
    • 5.4.2 Financial Analysis
    • 5.4.3 Segmental &Regional Analysis
    • 5.4.4 Research & Development Expenses
  • 5.5 Ironwood Pharmaceuticals, Inc.
    • 5.5.1 Company Overview
    • 5.5.2 Financial Analysis
    • 5.5.3 Regional Analysis
    • 5.5.4 Research & Development Expenses
  • 5.6 Eisai Co., Ltd.
    • 5.6.1 Company Overview
    • 5.6.2 Financial Analysis
    • 5.6.3 Segmental and Regional Analysis
    • 5.6.4 Research & Development Expenses
  • 5.7 Medigus Ltd.
    • 5.7.1 Company Overview
    • 5.7.2 Financial Analysis
    • 5.7.3 Segmental and Regional Analysis
    • 5.7.4 Research & Development Expenses
  • 5.8 Sebela Pharmaceuticals
    • 5.8.1 Company Overview
    • 5.8.2 Recent strategies and developments:
      • 5.8.2.1 Partnerships, Collaborations, and Agreements:
  • 5.9 Phathom Pharmaceuticals, Inc.
    • 5.9.1 Company Overview
    • 5.9.2 Research & Development Expenses
    • 5.9.3 Recent strategies and developments:
      • 5.9.3.1 Partnerships, Collaborations, and Agreements:
  • 5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
    • 5.10.1 Company Overview
    • 5.10.2 Recent strategies and developments:
      • 5.10.2.1 Product Launches and Product Expansions:

LIST OF TABLES

  • TABLE 1 Global Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 2 Global Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 3 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Global Antacids Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Antacids Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Proton Pump Inhibitors (PPIs) Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Proton Pump Inhibitors (PPIs) Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global H2 Receptor Blockers Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global H2 Receptor Blockers Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Pro-kinetic Agents Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Pro-kinetic Agents Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2022 - 2028, USD Million
  • TABLE 15 North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 16 North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 17 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 18 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 19 North America Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 20 North America Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 21 North America Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 22 North America Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 23 North America H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 24 North America H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 25 North America Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 26 North America Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 27 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 28 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 29 US Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 30 US Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 31 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 32 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 33 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 34 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 35 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 36 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 37 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 38 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 39 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 40 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 41 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 42 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 43 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 44 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 45 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 46 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 47 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 48 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 49 Europe Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 50 Europe Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 51 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 52 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 53 Europe H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 54 Europe H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 55 Europe Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 56 Europe Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 57 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 58 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 59 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 60 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 61 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 62 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 63 UK Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 64 UK Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 65 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 66 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 67 France Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 68 France Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 69 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 70 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 71 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 72 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 73 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 74 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 75 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 76 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 77 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 78 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 79 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 80 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 81 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 82 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 83 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 84 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 85 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 86 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 87 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 88 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 89 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 90 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 91 Asia Pacific Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 92 Asia Pacific Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 93 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Asia Pacific H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Asia Pacific H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Asia Pacific Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Asia Pacific Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 100 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 101 China Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 102 China Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 103 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 104 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 105 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 106 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 107 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 108 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 109 India Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 110 India Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 111 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 112 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 113 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 114 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 115 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 116 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 117 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 118 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 119 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 120 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 121 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 122 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 123 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 124 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 125 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 126 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 127 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 128 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 129 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 130 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 131 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 132 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 133 LAMEA Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 134 LAMEA Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 135 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 136 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 137 LAMEA H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 138 LAMEA H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 139 LAMEA Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 140 LAMEA Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 141 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 142 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 143 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 144 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 145 2023
  • TABLE 146 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 147 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 148 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 149 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 150 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 151 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 152 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 153 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 154 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 155 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 156 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 157 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 158 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 159 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 160 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 161 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 162 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 163 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 164 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 165 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 166 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 167 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 168 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 169 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 170 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 171 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 172 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 173 KEY INFORMATION - AstraZeneca PLC
  • TABLE 174 Key Information - GlaxoSmithKline PLC
  • TABLE 175 Key information -Johnson & Johnson
  • TABLE 176 Key Information - Ironwood Pharmaceuticals, Inc.
  • TABLE 177 Key Information - Eisai Co., Ltd.
  • TABLE 178 Key Information - Medigus Ltd.
  • TABLE 179 Key Information - Sebela Pharmaceuticals
  • TABLE 180 Key Information - Phathom Pharmaceuticals, Inc.
  • TABLE 181 Key Information - Camber Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2021
  • FIG 3 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2028
  • FIG 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2028, USD Million
  • FIG 5 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2021
  • FIG 6 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2028
  • FIG 7 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2028, USD Million